VIENNA, Va.–(BUSINESS WIRE)–
CEL-SCI Corporation (NYSE MKT: CVM) today announced that in April it enrolled 31 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). April marks the 4th consecutive month of record enrollment for CEL-SCI this year following January, February and March, 2015. Enrollment was 24 patients in January, 25 patients in February and 29 patients in March. Four hundred thirty-seven (437) patients have been enrolled in the Phase III study as of April 30, 2015.
“We are very pleased with the enrollment, particularly since there were major holidays this month that made enrollment much more difficult,” stated CEL-SCI Chief Executive Officer Geert Kersten.
About Multikine Phase III Study
The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care (SOC) vs. subjects who are treated with SOC only.
